Friday, 13 April 2018

Share Market In Karur

Share Market In Karur

Eris Lifesciences Limited (Eris), engaged in manufacturing of branded generic drugs, has built a strong positioning in the Cardiovascular, Anti diabetics, Vitamins, Gastroenterology and Anti-infective segments.

It is the 2nd fastest growing (22%CAGR over FY13-17) among the top 35 pharma companies, operating in India, in terms of sales.

It derives 100% of its revenue from the Indian Pharmaceutical Market (IPM).

It is the fastest growing (28.9% CAGR over FY13-17) company in the chronic segment category among the 25 largest pharmaceutical companies in IPM, i.e.,

over 2x growth (29% CAGR over FY13-17) of the IPM Chronic Segment. With the acquisition of Strides, Eris entered the Central Nervous System segment.

Strides revenue for FY17 amounted to Rs 181 crore with 70% revenue contributed by 3 Southern States of India.

For better investment contact
KKP CAPITAL, 9894333189

No comments:

Post a Comment